EXG001-307 injection

BIOLOGICAL3 trials

Sponsors

Hangzhou Jiayin Biotech Ltd

Conditions

Spinal Muscular Atrophy (SMA)Spinal Muscular Atrophy Type IType I Spinal Muscular Atrophy

Early Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type I

CompletedNCT06576388

Hangzhou Jiayin Biotech LtdType I Spinal Muscular Atrophy

Start: 2022-01-21End: 2024-01-21Updated: 2024-08-28

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

Enrolling by invitationNCT06888661

Hangzhou Jiayin Biotech LtdSpinal Muscular Atrophy (SMA)

Start: 2025-03-10End: 2026-12-30Target: 4Updated: 2025-03-21

Phase 1

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1

Enrolling by invitationNCT05614531

Hangzhou Jiayin Biotech LtdSpinal Muscular Atrophy Type I

Start: 2023-02-16End: 2025-08-31Target: 12Updated: 2024-09-19

Related Papers

Efficacy and preliminary safety assessment of EXG001-307 AAV gene therapy for spinal muscular atrophy.

2025-04-181 citations